Serrano-Candelas E - Search Results

1

MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia.

Navinés-Ferrer A, Serrano-Candelas E, Lafuente A, Muñoz-Cano R, Martín M, Gastaminza G. Navinés-Ferrer A, et al. Sci Rep. 2018 Aug 2;8(1):11628. doi: 10.1038/s41598-018-29965-8. Sci Rep. 2018. PMID: 30072729 Free PMC article.

2

The adaptor 3BP2 is required for KIT receptor expression and human mast cell survival.

Ainsua-Enrich E, Serrano-Candelas E, Álvarez-Errico D, Picado C, Sayós J, Rivera J, Martín M. Ainsua-Enrich E, et al. J Immunol. 2015 May 1;194(9):4309-18. doi: 10.4049/jimmunol.1402887. Epub 2015 Mar 25. J Immunol. 2015. PMID: 25810396 Free PMC article.

3

Comparable actions of omalizumab on mast cells and basophils.

Serrano-Candelas E, Martinez-Aranguren R, Valero A, Bartra J, Gastaminza G, Goikoetxea MJ, Martín M, Ferrer M. Serrano-Candelas E, et al. Clin Exp Allergy. 2016 Jan;46(1):92-102. doi: 10.1111/cea.12668. Clin Exp Allergy. 2016. PMID: 26509363

4

IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.

Navinés-Ferrer A, Serrano-Candelas E, Molina-Molina GJ, Martín M. Navinés-Ferrer A, et al. J Immunol Res. 2016;2016:8163803. doi: 10.1155/2016/8163803. Epub 2016 Dec 21. J Immunol Res. 2016. PMID: 28097159 Free PMC article. Review.

5

Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells.

Serrano-Candelas E, Martínez-Aranguren R, Vega O, Gastaminza G, Bartra J, Audicana MT, Núñez-Córdoba JM, Algorta J, Valero A, Martin M, Ferrer M. Serrano-Candelas E, et al. Sci Rep. 2017 Aug 21;7(1):8985. doi: 10.1038/s41598-017-09361-4. Sci Rep. 2017. PMID: 28827590 Free PMC article.

6

Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.

Serrano-Candelas E, Ainsua-Enrich E, Navinés-Ferrer A, Rodrigues P, García-Valverde A, Bazzocco S, Macaya I, Arribas J, Serrano C, Sayós J, Arango D, Martin M. Serrano-Candelas E, et al. Mol Oncol. 2018 Aug;12(8):1383-1397. doi: 10.1002/1878-0261.12332. Epub 2018 Jun 30. Mol Oncol. 2018. PMID: 29885053 Free PMC article.

7

Myo1f, an Unconventional Long-Tailed Myosin, Is a New Partner for the Adaptor 3BP2 Involved in Mast Cell Migration.

Navinés-Ferrer A, Ainsua-Enrich E, Serrano-Candelas E, Sayós J, Martin M. Navinés-Ferrer A, et al. Front Immunol. 2019 May 9;10:1058. doi: 10.3389/fimmu.2019.01058. eCollection 2019. Front Immunol. 2019. PMID: 31143189 Free PMC article.

8

Activation of Siglec-7 results in inhibition of in vitro and in vivo growth of human mast cell leukemia cells.

Landolina N, Zaffran I, Smiljkovic D, Serrano-Candelas E, Schmiedel D, Friedman S, Arock M, Hartmann K, Pikarsky E, Mandelboim O, Martin M, Valent P, Levi-Schaffer F. Landolina N, et al. Pharmacol Res. 2020 Aug;158:104682. doi: 10.1016/j.phrs.2020.104682. Epub 2020 Feb 5. Pharmacol Res. 2020. PMID: 32035162 Free article.

9

MYO1F Regulates IgE and MRGPRX2-Dependent Mast Cell Exocytosis.

Navinés-Ferrer A, Ainsua-Enrich E, Serrano-Candelas E, Proaño-Pérez E, Muñoz-Cano R, Gastaminza G, Olivera A, Martin M. Navinés-Ferrer A, et al. J Immunol. 2021 May 15;206(10):2277-2289. doi: 10.4049/jimmunol.2001211. Epub 2021 May 3. J Immunol. 2021. PMID: 33941653 Free PMC article.

10

Author Correction: MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia.

Navinés-Ferrer A, Serrano-Candelas E, Lafuente A, Muñoz-Cano R, Martín M, Gastaminza G. Navinés-Ferrer A, et al. Sci Rep. 2021 Jun 8;11(1):12449. doi: 10.1038/s41598-021-91844-6. Sci Rep. 2021. PMID: 34103639 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

30 results

Search Page